Brilliant Blue Versus Indocyanine Green

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2007 by University of Cologne.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
University of Cologne
ClinicalTrials.gov Identifier:
NCT01083004
First received: March 8, 2010
Last updated: April 15, 2011
Last verified: October 2007
  Purpose

A study of non-inferiority design comparing brilliant blue and indocyanine green as intraoperative dye in macular pucker and macular hole.


Condition Intervention Phase
Macular Pucker
Macular Hole
Vitreoretinal Surgery
Procedure: Indocyanine green
Procedure: Brilliant blue arm
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomized Study Comparing Brilliant Blue and Indocyanine Green as Intravitreal Dye in Macular Pucker and Macular Hole

Resource links provided by NLM:


Further study details as provided by University of Cologne:

Primary Outcome Measures:
  • Best corrected far visual acuity (ETDRS) [ Time Frame: 1 year postoperative ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Reading ability (Radner) [ Time Frame: 1 Year ] [ Designated as safety issue: Yes ]
  • Optical coherence tomography [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Estimated Enrollment: 50
Study Start Date: January 2008
Estimated Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Indocyanine green arm Procedure: Indocyanine green
Using indocyanine green as intraoperative dye
Active Comparator: Brilliant blue Procedure: Brilliant blue arm
Using brilliant blue as intraoperative dye

  Eligibility

Ages Eligible for Study:   50 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • age over 50
  • macular pucker or macular hole with subjective disturbances
  • All phakic or pseudophakic patients
  • far visual acuity better than 20/400
  • able to read, understand, and willing to sign the informed consent form

Exclusion Criteria:

  • any other ocular disease or conditions compromising the visual acuity other than macular hole or macular pucker
  • prior vitreoretinal surgery in the study eye
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01083004

Contacts
Contact: Albert Caramoy, MD 004902214784308 acaramoy@yahoo.co.uk

Locations
Germany
Center of Ophthalmology, University of Cologne Recruiting
Cologne, NRW, Germany, 50924
Contact: Albert Caramoy, MD    004902214784308    acaramoy@yahoo.co.uk   
Sub-Investigator: Albert Caramoy, MD         
Principal Investigator: Bernd Kirchhof, MD         
Sponsors and Collaborators
University of Cologne
Investigators
Principal Investigator: Bernd Kirchhof, MD University of Cologne, Center of Ophthalmology, 50924 Cologne, Germany
  More Information

No publications provided

Responsible Party: Prof. Dr. B. Kirchhof, University of Cologne
ClinicalTrials.gov Identifier: NCT01083004     History of Changes
Other Study ID Numbers: BlueIce001
Study First Received: March 8, 2010
Last Updated: April 15, 2011
Health Authority: Germany: University of Cologne

Keywords provided by University of Cologne:
dye
internal limiting membrane
macular hole
macular pucker

Additional relevant MeSH terms:
Retinal Perforations
Retinal Diseases
Eye Diseases

ClinicalTrials.gov processed this record on April 17, 2014